Genocea Biosciences (LTS:0A51) EPS (Basic): $-0.52 (TTM As of Mar. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A51 Genocea Biosciences Inc LTS:0A51
16 GF Score
Price $0.00
View Full Analysis

What is Genocea Biosciences EPS (Basic)?

Genocea Biosciences LTS:0A51 16 EPS (Basic) is $-0.52 as of Mar. 2022. GuruFocus rates LTS:0A51 with a GF Score™ of 16/100.

Genocea Biosciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2022 was $-0.22. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2022 was $-0.52.

Genocea Biosciences's EPS (Diluted) for the three months ended in Mar. 2022 was $-0.22. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-0.66.

Genocea Biosciences's EPS without NRI for the three months ended in Mar. 2022 was $-0.22. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was -0.94.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Genocea Biosciences  (LTS:0A51) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Genocea Biosciences EPS (Basic) Related Terms

Genocea Biosciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Genocea Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genocea Biosciences EPS (Basic) Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.84 -2.69 -1.89 -0.98 -0.48

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.06 -0.05 -0.19 -0.22
LTS:0A51
16GF Score
Genocea Biosciences Inc LTS:0A51
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genocea Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Genocea Biosciences's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as

Basic EPS (A: Dec. 2021 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-33.196-0)/68.575
=-0.48

Genocea Biosciences's Basic EPS for the quarter that ended in Mar. 2022 is calculated as

Basic EPS (Q: Mar. 2022 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-15.978-0)/71.120
=-0.22

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.52 mean?
Genocea Biosciences (LTS:0A51) has a EPS (Basic) of $-0.52 as of Mar. 2022. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Genocea Biosciences and its competitors.
Is Genocea Biosciences' EPS (Basic) too high?
Genocea Biosciences' current EPS (Basic) is $-0.52. Overall, Genocea Biosciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Genocea Biosciences' EPS (Basic) compare to FNAM and BXRX?
Genocea Biosciences' EPS (Basic) of $-0.52 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Genocea Biosciences and its competitors. Genocea Biosciences's current EPS (Basic) is $-0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genocea Biosciences stock overvalued right now?
Genocea Biosciences (LTS:0A51) has a current EPS (Basic) of $-0.52. The current EPS (Basic) is $-0.52. Genocea Biosciences' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Genocea Biosciences (LTS:0A51), the current EPS (Basic) is $-0.52 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genocea Biosciences Business Description

Address 100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
16GF Score

Get the complete analysis for LTS:0A51

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price